Elsevier

Lung Cancer

Volume 35, Issue 1, January 2002, Pages 1-7
Lung Cancer

Original article
Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial

https://doi.org/10.1016/S0169-5002(01)00288-4Get rights and content

Abstract

Background: No standard treatment is defined for elderly patients with small cell lung cancer (SCLC). Carboplatin and etoposide are highly active agents against SCLC. In this study, we evaluated the activity and toxicity of a combination of these two agents. Patients and methods: Thirty-four untreated patients with limited or extensive SCLC and median age of 73.9 years entered the study. Chemotherapy consisted of carboplatin i.v. on day 1 (AUC 5 using Calvert's formula) and etoposide 100 mg/m2 given orally on days 1–5, every 4 weeks, and thoracic irradiation was given to limited disease patients after chemotherapy. Results: The overall response rates was 59% (95% CI: 43–76). The median survival for all patients was 37 weeks (range 3–76 weeks). The toxicity was mainly haematological with grade 3–4 neutropenia in 59% of courses, febrile neutropenia in 15% of courses, and toxic death in 9% of patients. Conclusion: The results of this regimen are disappointing with worse response and survival, and more haematological toxicity than expected and previously reported, despite the use of Calvert's formula. Possible explanations are the use of etoposide per os rather than i.v., the frequent comorbidities of older patients and the inclusion of patients with poor prognosis factors.

Introduction

Demographic trends in Western countries show a steady ageing of the population: from 1950 to 1990, the over-65 years group has grown from 8 to 13% of the population and is expected to reach 20% in 2030. Close to 60% of all cancer deaths arise in persons aged more than 65 years [1]. Lung cancer is the leading cause of cancer-related mortality in these populations, and occurs in greater than 60% of cases in patients older than 65 years. This proportion should enhance with the increasing life expectancy [1], [2] and is certainly underestimated since elderly patients with respiratory symptoms have less investigations than their younger counterparts [3], [4]. Small cell lung cancer (SCLC) accounts for 25% of all newly diagnosed cases of lung cancer beyond 70 years [4], [5]. Although modest but sure advances were recently allowed in SCLC by combined modality treatment with radiation therapy and systemic chemotherapy [6], older patients have not yet benefited from these improvements, and SCLC remains of poor prognosis in this group [4], [5], [7]. A physiologic decline in the function of vital organs, especially the liver and the kidneys, as comorbidities and polymedications frequently associated with ageing, might result in a greater toxicity of cytotoxic agents [5], [8], [9].

Carboplatin, an active analogue of cisplatin, has the advantages of easier administration, and less gastrointestinal, renal, auditive and neurologic toxicities. Its haematological toxicity remains limiting, particularly in elderly patients [10], [11], but can be reduced by individual dose adaptation, using Calvert's formula [12].

Single-agent etoposide is also highly active in SCLC, producing tumor regression in more than 50% untreated patients [13]. The efficacy of etoposide is schedule-dependent, with a greater antitumoral activity of a same dose given over 5 consecutive days rather than a single continuous infusion [14]. Oral administration is possible with proven efficacy and good tolerance in elderly SCLC patients [15], [16], [17].

We therefore designed a phase II study evaluating the combination of carboplatin and oral etoposide in the treatment of elderly patients with SCLC.

Section snippets

Patient selection

Selection criteria were age ≥70 years, SCLC confirmed by histology or cytology, limited or extensive disease (including cerebral metastasis), no previous chemotherapy or radiation therapy, no history of prior malignant disease, and a WHO performance status (PS) ≤2. Patients with uncontrolled severe heart disease, neutrophil count <1.5×109/l, platelet count <100×109/1, or a creatinine clearance <20 ml/min were excluded. The study protocol was approved by the local ethics committees and all

Patients characteristics

From june 1994 to October 1997, 34 previously untreated patients with SCLC entered the study. Among them, 27 patients were included in three of the participating study centres. Their main characteristics are listed in Table 1. The median age was 73.7 years (range 70–79). Most patients were men (88%). Eighteen patients (53%) had a WHO PS of zero or one, and the remaining 16 patients (47%) had PS 2. Despite the minimal investigations carried out, only six patients (18%) were defined as having LD,

Discussion

Most of prospective trials about SCLC treatment have systematically excluded elderly patients in the past, resulting in a relative lack of data in this population. Single agent therapy with etoposide has shown significant activity and mild toxicity, and so has first been considered as an interesting option for such patients, specially with its oral form [16]. However, two recent randomized studies in elderly or poor-prognosis SCLC patients demonstrated the superiority of intravenous combination

Conclusion

Despite a confirmed activity in SCLC of aged people, the combination of carboplatin and oral etoposide showed in this study lower response rates, shorter survival and higher toxicity than expected. With regards to these disappointing results, such a schedule, although presumed adapted, is certainly not a gentle treatment, and cannot be recommended for such aged patients, and particularly those with poor PS and extensive disease. Optimal modalities of administration have to be specified, and

References (29)

  • A. Byrne et al.

    Small cell lung cancer in the elderly

    Semin. Oncol.

    (1994)
  • D.H. Johnson

    Small cell lung cancer in the elderly patient

    Semin. Oncol.

    (1997)
  • M.F. Muers et al.

    Management of lung cancer

    Thorax

    (1996)
  • D. Raghavan et al.

    Carboplatin-containing regimens for small cell lung cancer: implications for management in the elderly

    Semin. Oncol.

    (1992)
  • Cited by (0)

    View full text